Aroa Biosurgery Ltd (ASX: ARX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Aroa Biosurgery Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Aroa Biosurgery Ltd (ASX: ARX)
Latest News
Share Fallers
Why 29Metals, Aroa Biosurgery, Mader, and Netwealth shares are falling
Share Fallers
Why Aroa Biosurgery, Bank of Queensland, Champion Iron, and Terracom shares are falling
Healthcare Shares
Morgans says these small cap ASX healthcare shares are buys with 50% upside
Broker Notes
Buy these 2 ASX health-tech shares that are ready to rocket: Wilson
52-Week Highs
4 ASX All Ordinaries shares hitting new 52-week highs today
52-Week Highs
5 ASX All Ords shares cracking new 52-week highs on Tuesday
52-Week Highs
2 ASX All Ords shares cracking new 52-week highs on Tuesday
Broker Notes
Buy 2 ASX shares for cutting-edge tech changing the world: expert
Healthcare Shares
The ASX All Ords share that's a better, cheaper buy than Polynovo: Wilsons
Share Gainers
Why Aroa Biosurgery, Cettire, Estia Health, and Weebit Nano shares are rising
Growth Shares
3 hot small-cap ASX growth shares Firetrail's backing right now
Broker Notes
Leading brokers name 3 ASX shares to buy today
Frequently Asked Questions
-
No, Aroa Biosurgery does not pay shareholder dividends at this time.
-
Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.
ARX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Aroa Biosurgery Ltd
Aroa Biosurgery Ltd (ASX: ARX) is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.
The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.
ARX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $0.57 | $0.02 | 3.67% | 132,446 | $0.55 | $0.57 | $0.55 |
26 Mar 2024 | $0.55 | $-0.03 | -5.17% | 237,317 | $0.57 | $0.58 | $0.55 |
25 Mar 2024 | $0.58 | $0.01 | 1.75% | 288,901 | $0.57 | $0.59 | $0.57 |
22 Mar 2024 | $0.57 | $0.03 | 5.61% | 642,840 | $0.54 | $0.58 | $0.54 |
21 Mar 2024 | $0.54 | $0.01 | 1.90% | 233,384 | $0.53 | $0.54 | $0.52 |
20 Mar 2024 | $0.53 | $0.03 | 6.00% | 201,406 | $0.51 | $0.53 | $0.51 |
19 Mar 2024 | $0.50 | $-0.02 | -3.85% | 223,482 | $0.52 | $0.52 | $0.49 |
18 Mar 2024 | $0.52 | $-0.01 | -1.89% | 435,904 | $0.53 | $0.53 | $0.51 |
15 Mar 2024 | $0.53 | $0.01 | 1.92% | 342,348 | $0.52 | $0.53 | $0.52 |
14 Mar 2024 | $0.52 | $0.01 | 1.94% | 272,458 | $0.52 | $0.54 | $0.52 |
13 Mar 2024 | $0.52 | $-0.02 | -3.74% | 241,434 | $0.53 | $0.54 | $0.52 |
12 Mar 2024 | $0.54 | $0.01 | 1.89% | 280,935 | $0.53 | $0.54 | $0.53 |
11 Mar 2024 | $0.53 | $-0.01 | -1.85% | 238,614 | $0.55 | $0.56 | $0.52 |
08 Mar 2024 | $0.54 | $-0.01 | -1.83% | 194,555 | $0.55 | $0.56 | $0.54 |
07 Mar 2024 | $0.55 | $-0.02 | -3.57% | 237,160 | $0.56 | $0.57 | $0.55 |
06 Mar 2024 | $0.56 | $-0.01 | -1.75% | 332,486 | $0.58 | $0.58 | $0.56 |
05 Mar 2024 | $0.57 | $0.01 | 1.77% | 58,760 | $0.57 | $0.58 | $0.57 |
04 Mar 2024 | $0.57 | $-0.01 | -1.75% | 198,500 | $0.57 | $0.58 | $0.57 |
01 Mar 2024 | $0.57 | $0.00 | 0.00% | 105,879 | $0.57 | $0.57 | $0.56 |
29 Feb 2024 | $0.57 | $-0.01 | -1.72% | 464,918 | $0.58 | $0.59 | $0.57 |
28 Feb 2024 | $0.58 | $0.01 | 1.75% | 104,033 | $0.57 | $0.58 | $0.57 |
27 Feb 2024 | $0.57 | $0.01 | 1.79% | 126,369 | $0.57 | $0.58 | $0.57 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
16 Feb 2024 | Philip McCaw | Buy | 326,000 | $187,450 |
On-market trade.
|
06 Sep 2023 | James (Jim) McLean | Exercise | 50,000 | $37,500 |
Exercise of options.
|
06 Sep 2023 | James (Jim) McLean | Buy | 50,000 | $37,500 |
Exercise of options.
|
11 Aug 2023 | Catherine Mohr | Issued | 210,686 | $185,403 |
Issue of options.
|
31 Mar 2023 | Steven (Steve) Engle | Issued | 172,620 | $181,251 |
Issue of options.
|
31 Mar 2023 | John Pinion II | Issued | 172,620 | $181,251 |
Issue of options.
|
31 Mar 2023 | Brian Ward | Issued | 2,575,483 | $2,704,257 |
Issue of options.
|
31 Mar 2023 | James (Jim) McLean | Issued | 258,929 | $271,875 |
Issue of options.
|
31 Mar 2023 | John Diddams | Issued | 172,620 | $181,251 |
Issue of options.
|
31 Mar 2023 | Philip McCaw | Issued | 172,620 | $181,251 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr John Flower Diddams | Non-Executive Director | Nov 2019 |
Mr Diddams is a resident of Australia and has over forty years of experience as a CFO, CEO, and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in several diverse industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors.
|
Mr Philip John McCaw | Non-Executive Director | Mar 2008 |
Mr McCaw is a resident of New Zealand and is the Founding Partner of Movac, one of New Zealands Venture Capital funds. He led the original investment round into AROA in 2008, has worked closely with the Company and has served on the Board since then. He is also Chair of the New Zealand Government's Startup Advisors Council, established to help identify and address the opportunities and challenges facing high growth start-up businesses. Phil has over 20 years of experience investing into New Zealand technology companies and helping to guide their growth. He was an early investor in Trade Me, New Zealand's leading on-line trading community, which was sold to Fairfax in 2006.
|
Mr James (Jim) Neil McLean | Non-Executive ChairmanNon-Executive Director | Aug 2011 |
Mr McLean is a resident of New Zealand. He has over 25 years of experience serving as chair, director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to AROA, current appointments include Chair of Prevar Limited and R J Hill Laboratories. He was Chair of the New Zealand Institute of Plant and Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as Deputy Chair. Jim was an executive and director of Genesis Research and Development Corporation during its early stages through to public listing.
|
Mr Steven (Steve) Barnard Engle | Non-Executive Director | Apr 2015 |
Mr Engle is a resident of the US. He has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic, and infectious disease areas. Steve is the CEO and executive director of Gradalis Inc a late-stage biopharmaceutical company focused on the development and commercialisation of personalized therapeutics to treat cancer. He is also the non-executive Chairman of the board of Prescient Therapeutics an ASX listed clinical stage oncology company, and executive Chairman of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. Steve also runs Averigon, an advisory firm to the life science industry on matters ranging from business development to management team coaching. He is also member of the Risk Committee.
|
Mr John Richard Pinion II | Non-Executive Director | Feb 2015 |
Mr Pinion II is a resident of the US. He has over 30 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe, and the Americas. His expertise and leadership spans engineering, quality, manufacturing, and translational sciences. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical QC. He is also Chair of Risk committee.
|
Mr Brian Roderick Ward | Chief Executive OfficerManaging Director | Sep 2007 |
Mr Ward is the founder of AROA and a resident of New Zealand. He has held senior corporate roles in life sciences and health care companies for more than 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development, and strategy having worked for several multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on several government and industry expert panels. Brian has been responsible for leading AROA's growth from start-up through to the present.
|
Dr Catherine Mohr | Non-Executive Director | Nov 2022 |
Dr Mohr is a New Zealand citizen and resident of the US. She has over 30 years of experience across fields, including engineering, healthcare, alternative energy, aerospace, and global entrepreneurship. Her expertise spans many areas related to AROA's next stage of growth, including medtech product research and development, FDA approvals, product commercialisation and surgery technology innovation. She has been President of the Intuitive Foundation since 2018. Prior to leading the Foundation, Catherine held senior roles at Intuitive Surgical, including Vice President of Strategy and Director of Medical Research. Intuitive Surgical is a pioneer in the robotic-assisted surgery field and developed the da Vinci surgical robotic system which is used in millions of surgical procedures across the globe every year. She is also a member of risk committee.
|
Ms Darla Hutton | Non-Executive Director | Mar 2024 |
Ms Hutton brings over 25 years of leadership expertise in life sciences commercial strategy, operations, sales, marketing and data analytics. She is currently Vice President of Commercial Operations and Marketing-Asia, at Silicon Valley-based Intuitive Surgical, Inc., the global leader in minimally invasive care.Ms Hutton has held roles of responsibility at Intuitive, including Vice President of Corporate Accounts-US and Vice President of Marketing, Market Access & Custom Hospital Analytics . Ms Hutton is also a member of the compans Diversity Council. Ms Hutton has previously held commercial positions at global medical technology and pharmaceutical companies, including Boston Scientific and GlaxoSmithKline
|
Ms Tracy Weimar | Joint Company Secretary | Jul 2020 |
-
|
Mr James Blair Agnew | Chief Financial OfficerJoint Company Secretary |
-
|
|
James Blair Agnew | Chief Financial OfficerJoint Company Secretary |
-
|
|
Barnaby May | Chief Scientific Officer |
-
|
|
Patrick Hunt | Director of Business Development |
-
|
|
Frazer Murray | Director of Global Marketing and Strategy |
-
|
|
Rachel Stuart | Director of People and Culture |
-
|
|
Neetha Alex-Kumar | General Counsel |
-
|
|
Tracy Weimar | Joint Company Secretary |
-
|
|
Brad Adams | VP - Commercial (USA) |
-
|
|
Rod Stanley | VP - Manufacturing Operations |
-
|
|
Isaac Mason | VP - Product Development |
-
|
|
Yasmin Winchester | VP - Quality Regulatory and Sustainability |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 47,694,722 | 13.90% |
Mr Brian Ward & Mrs Tracey Ward <Arawai No 2 A/C> | 33,125,800 | 9.65% |
J P Morgan Nominees Australia Pty Limited | 31,448,545 | 9.17% |
HSBC Custody Nominees (Australia) Limited | 24,111,683 | 7.03% |
National Nominees Limited | 20,287,882 | 5.91% |
Phil Mccaw <Mcsyth Capital Invest A/C> | 19,751,154 | 5.75% |
Richard Abbott <Jester 002 Investment A/C> | 13,043,020 | 3.80% |
Aspire Nz Seed Fund Ltd | 12,689,627 | 3.70% |
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 10,422,463 | 3.04% |
BNP Paribas Noms (Nz) Ltd <Drp> | 8,261,303 | 2.41% |
Custodial Services Limited <Beneficiaries Holding A/C> | 6,846,246 | 2.00% |
Bnp Paribas Noms Pty Ltd <Drp> | 6,682,320 | 1.95% |
K One W One (No 3) Ltd | 5,882,550 | 1.71% |
Sharon Bryant <Ot Investment A/C> | 4,372,267 | 1.27% |
Christopher David Astley Milne | 3,213,022 | 0.94% |
K One W One Ltd | 3,041,226 | 0.89% |
Gft 2 Co Pty Limited <Gft 2 A/C> | 2,820,912 | 0.82% |
James Mclean | 2,777,108 | 0.81% |
Mesynthes Nominees Ltd | 2,568,600 | 0.75% |
Barnaby May | 2,449,500 | 0.71% |